HeartSciences (NASDAQ:HSCS) Releases Quarterly Earnings Results, Misses Estimates By $0.22 EPS

HeartSciences (NASDAQ:HSCS) posted its quarterly earnings data on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.22), Zacks reports.

HeartSciences Stock Performance

Shares of HeartSciences stock traded down $0.05 during trading on Friday, hitting $2.39. 8,205 shares of the company’s stock traded hands, compared to its average volume of 86,167. HeartSciences has a 1 year low of $1.63 and a 1 year high of $4.30. The business has a 50-day simple moving average of $2.27 and a 200-day simple moving average of $2.50. The stock has a market capitalization of $7.60 million, a P/E ratio of -0.61 and a beta of 1.78. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 1.04.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in HeartSciences stock. Geode Capital Management LLC increased its stake in HeartSciences Inc. (NASDAQ:HSCS) by 110.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,928 shares of the company’s stock after purchasing an additional 14,150 shares during the quarter. Geode Capital Management LLC owned 0.85% of HeartSciences worth $83,000 at the end of the most recent quarter. Institutional investors and hedge funds own 17.24% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, HeartSciences currently has an average rating of “Hold” and an average price target of $8.00.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.